Clinical Trial Detail

NCT ID NCT02229149
Title Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors US Oncology Research
Indications

Her2-receptor positive breast cancer

Therapies

Paclitaxel

Docetaxel

Pertuzumab + Trastuzumab

Nab-paclitaxel

Vinorelbine

Trastuzumab

Capecitabine

Age Groups: adult

Additional content available in CKB BOOST